Kodiak Sciences (K27) Price & Analysis

2 Followers

K27 Stock Chart & Stats

€34.00

€0.20(2.26%)

At close: Jan 08 4:00 PM EST

€34.00

€0.20(2.26%)

Day’s Range― - ―

52-Week Range€4.67 - €39.74

Previous CloseN/A

Volume800.00

Average Volume (3M)13.00

Market Cap

€2.24B

Enterprise Value€2.34K

Total Cash (Recent Filing)€169.53M

Total Debt (Recent Filing)€155.99M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Aug 19, 2026

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.17

Shares Outstanding62,578,440

10 Day Avg. Volume34

30 Day Avg. Volume13

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)9.45

Price to Sales (P/S)0.00

P/FCF Ratio-10.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€52.33

Price Target Upside53.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-3.25

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Ophthalmology PipelineA concentrated, clinical-stage focus on retinal diseases and a proprietary drug design/delivery approach is a durable strategic advantage: if clinical readouts validate extended ocular durability, the company can claim differentiated dosing and adoption benefits versus competitors, supporting long-term commercial positioning in a specialist therapeutic niche.

Improving Loss And Burn TrendMeaningful narrowing of losses and improved cash burn versus prior years indicates management is stabilizing operations. Sustained improvement extends runway and reduces near-term financing frequency, enabling the company to progress clinical milestones with less dilution risk — a durable operational improvement if maintained through upcoming trials.

Lowering LeverageA reduction in reported debt-to-equity provides structural balance-sheet relief for a pre-revenue biotech. Moderate leverage lowers solvency risk and preserves strategic optionality (e.g., partner deals or structured financings). If this trend persists, it improves the company's ability to fund clinical programs without excessive creditor pressure.

Bears Say

No RevenueZero revenue is a fundamental constraint: the business model remains fully dependent on successful clinical outcomes and external funding. Until a commercial product generates recurring sales, the company faces structural uncertainty around sustainable cash generation and must rely on capital markets or partners to fund ongoing R&D.

Persistent Negative Cash FlowLarge, persistent negative operating and free cash flow indicates losses convert to real cash outflows rather than non-cash accounting charges. This ongoing burn structurally increases funding requirements, raises dilution risk, and constrains the company's ability to self-fund development or scale operations absent a revenue inflection or material partnership.

Eroding Equity Base & Funding RiskA materially reduced equity base signals prolonged losses and weaker capital cushions. This erosion reduces financial flexibility, elevates the probability of dilutive financings, and limits ability to absorb clinical setbacks. Long-term viability hinges on clinical progress or sizable external capital/partnerships.

Kodiak Sciences News

Kodiak Sciences: Buy Rating Reiterated as KSI-101’s MESI Opportunity Supports Maintained $65 Price Target

Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on Kodiak Sciences. The associated price target...

23d ago

KOD

Kodiak Sciences Stockholders Back Directors and Governance Proposals

Kodiak Sciences ( ($KOD) ) just unveiled an update. On June 2, 2026, Kodiak Sciences Inc. held its...

2M ago

KOD

Kodiak Sciences upgraded to Buy from Neutral at Chardan

Chardan upgraded Kodiak Sciences (KOD) to Buy from Neutral with a $61 price target “Stellar results” from GLOW2,...

2M ago

KOD

Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)

Kodiak ended Q1 with $169.5M cash and cash equivalents and believes that current cash and cash equivalents will...

3M ago

KOD

Kodiak Sciences falls -8.7%

Kodiak Sciences (KOD) is down -8.7%, or -$3.72 to $39.09. Published first on TheFly – the ultimate source...

4M ago

KOD

3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

4M ago

KOD

PVLA

Morning News Wrap-Up 4/1/26: Today’s Biggest Stock Market Stories!

Stocks climbed today alongside earnings reports, analysts updates, and other economic happenings. ...

4M ago

AMD

Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings

Kodiak Sciences stock climbed on Wednesday alongside analyst updates after the company’s most recent earnings report. ...

4M ago

KOD

Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year

Kodiak reported Q4 results yesterday”Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from...

4M ago

KOD

Kodiak Sciences rises 10.7%

Kodiak Sciences (KOD) is up 10.7%, or $4.07 to $42.19. Published first on TheFly – the ultimate source...

4M ago

KOD

Reiterating Buy on Kodiak: GLOW2 Validates Zenkuda’s Durable Efficacy and Multi‑Indication Path to Accelerated BLA

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Kodiak Sciences today and set a price target...

4M ago

KOD

Kodiak Sciences options imply 7.3% move in share price post-earnings

Pre-earnings options volume in Kodiak Sciences (KOD) is 2.1x normal with puts leading calls 9:2. Implied volatility suggests...

4M ago

KOD

Kodiak Sciences price target raised to $80 from $50 at UBS

UBS raised the firm’s price target on Kodiak Sciences (KOD) to $80 from $50 and keeps a Buy...

4M ago

KOD

Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results

Kodiak Sciences ( ($KOD) ) just unveiled an update. On March 26, 2026, Kodiak Sciences reported positive topline...

4M ago

KOD

K27 FAQ

What was Kodiak Sciences’s price range in the past 12 months?

Kodiak Sciences lowest stock price was €4.67 and its highest was €39.74 in the past 12 months.

What is Kodiak Sciences’s market cap?

Kodiak Sciences’s market cap is €2.24B.

When is Kodiak Sciences’s upcoming earnings report date?

Kodiak Sciences’s upcoming earnings report date is Aug 19, 2026 which is in 27 days.

How were Kodiak Sciences’s earnings last quarter?

Currently, no data Available

Is Kodiak Sciences overvalued?

According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kodiak Sciences pay dividends?

Kodiak Sciences does not currently pay dividends.

What is Kodiak Sciences’s EPS estimate?

Kodiak Sciences’s EPS estimate is -0.84.

How many shares outstanding does Kodiak Sciences have?

Kodiak Sciences has 62,578,440 shares outstanding.

What happened to Kodiak Sciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kodiak Sciences?

Currently, no hedge funds are holding shares in DE:K27

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kodiak Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

2.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kodiak Sciences

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Kodiak Sciences (K27) Earnings & Revenues

Historic Earnings Reports

K27 Stock 12 Month Forecast

Average Price Target

€52.33

▲(53.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","57":"€57","15.75":"€15.75","29.5":"€29.5","43.25":"€43.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.69497925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€56.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.333827,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€52.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.8449052,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€48.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,15.75,29.5,43.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.85,35.60730609615385,37.364612192307696,39.12191828846154,40.879224384615384,42.63653048076923,44.39383657692308,46.151142673076926,47.90844876923077,49.66575486538461,51.42306096153847,53.18036705769231,54.937673153846156,{"y":56.69497925,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.85,35.27183284615385,36.6936656923077,38.11549853846154,39.537331384615385,40.95916423076923,42.38099707692308,43.80282992307693,45.22466276923077,46.646495615384616,48.068328461538464,49.490161307692304,50.91199415384615,{"y":52.333827,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.85,35.00345424615385,36.15690849230769,37.31036273846154,38.463816984615384,39.617271230769234,40.770725476923076,41.924179723076925,43.07763396923077,44.23108821538462,45.38454246153846,46.53799670769231,47.69145095384616,{"y":48.8449052,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.064,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.635,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >